Fed. Circ. Finds No Standing For Appeal Of PTAB Drug Ruling
The Federal Circuit ruled Monday that medical research company Phigenix cannot appeal an inter partes review decision upholding a patent it challenged on a Genentech cancer drug, marking the first time...To view the full article, register now.
Already a subscriber? Click here to view full article